X-ray structure of HIV-1 protease in situ product complex

Proteins: Structure, Function and Bioinformatics

Volumn 74, Issue 3, 2009, Pages 594-602

  Bihani, Subhash ^a   Das, Amit ^a   Prashar, Vishal ^a   Ferrer, J L ^b   Hosur, M V ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Catalysis; Hiv 1 protease; Inhibitor; Reaction intermediate; Transition state; X ray crystallography

Indexed keywords

ASPARTIC ACID; NITROGEN; PROTEINASE; OLIGOPEPTIDE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; SERYL GLUTAMINYL ASPARAGINYL TYROSYL PROLYL ISOLEUCYL VALYL GLUTAMINE; SERYL-GLUTAMINYL-ASPARAGINYL-TYROSYL-PROLYL-ISOLEUCYL-VALYL-GLUTAMINE;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTON TRANSPORT; X RAY CRYSTALLOGRAPHY; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; METABOLISM; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ASPARTIC ACID; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HYDROGEN BONDING; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY;

EID: 59849127517     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22174     Document Type: Article

References (30)

1. Heagarty MC. AIDS: the battle rages on. Issues in science and technology online. Summer 2003.http://www.nap.edu/issues/19.4/heagarty html#top.
2. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, Sigal IS. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85:4686-4690.
3. Wolfenden R. Conformational aspects of inhibitor design: enzyme- substrate interactions in the transition state. Bioorg Med Chem 1999; 7:647-652.
4. Wlodawer A Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27:249-284.
5. Rose RB, Craik CS, Douglas NL, Stroud RM. Three-dimensional structures of HIV-1 and SIV protease product complexes. Biochemistry 1996; 35:12933-12944.
6. Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002; 10:369-381.
7. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol 2002; 77:1306-1315.
8. Hyland LJ, Tomaszek TA, Jr, Meek TD. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 1991; 30:8454-8463.
9. Lee H, Darden TA, Pedersen LG. An ab initio quantum mechanical model for the catalytic mechanism of HIV-1 protease. J Am Chem Soc 1996; 118:3946-3950.
10. Liu H, Muller-Plathe F, van Gunsteren WF. A combined quantum/ classical molecular dynamics study of the catalytic mechanism of HIV protease. J Mol Biol 1996; 261:454-469.
11. Park H, Suh J, Lee S. Ab initio studies on the catalytic mechanism of aspartic proteinases: nucleophilic versus general acid/general base mechanism. J Am Chem Soc 2000; 122:3901-3908.
12. Rodriguez EJ, Angeles TS, Meek TD. Use of nitrogen-15 kinetic isotope effects to elucidate details of the chemical mechanism of human immunodeficiency virus 1 protease. Biochemistry 1993; 32:12380-12385.
13. Silva AM, Cachau RE, Sham HL, Erickson JW. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J Mol Biol 1996; 255: 321-346.
14. Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrickson RL, Schneider J, Kent SBH, Wlodawer A. Structure at 2.5-Å resolution of chemically synthesized human immunodeficiency type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 1991; 30:1600-1609.
15. Northrop DB. Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc Chem Res 2001; 34:790-797.
16. Kovalevsky AV, Chumanevich AA, Liu F, Louis JM, Weber IT. Caught in the act: the 1.5̊-A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry 2007; 46:14854-14864.
17. Brik A, Wong C-H. HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 2003; 1:5-14.
18. Dunn BM. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 2002; 102:4431-4458.
19. Cheng Y-SE, Yin FH, Foundling S, Blomstrom D, Kettner CA. Stability and activity of human immunodeficiency virus protease: comparison of a natural dimer with a homologous single chain tethered dimer. Proc Natl Acad Sci USA 1990; 87:9660-9664.
20. Pillai B, Bhat ,SV, Kannan KK, Hosur MV. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction. Acta Crystallogr D 2004; 60:594-596.
21. Pillai B, Kannan KK, Hosur MV. 1.9 A X-ray study shows closed flap conformation in crystals of tethered HIV-1 PR. Proteins 2001; 43:57-64.
22. Das A, Prashar V, Mahale S, Serre L, Ferrer J-L, Hosur MV. Crystal structure of HIV-1 protease in situ product complex and observation of a low-barrier hydrogen bond between catalytic aspartates. Proc Natl Acad Sci USA 2006; 103:18464-18469.
23. Kumar M, Prashar V, Mahale S, Hosur MV. Observation of a tetrahedral reaction intermediate in HIV-1 protease substrate complex. Biochem J 2005; 389:365-371.
24. Cleland WW, Frey PA, Gerlt JA. The low barrier hydrogen bond in enzymatic catalysis. J Biol Chem 1998; 273:25529-25532.
25. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 1993; 26:795-800.
26. Briinger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse- Kunstleve RW, Jiang J-S, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallogr NMR Syst Acta Crystallogr D 1998; 54:905-921.
27. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991; 47:110-119.
28. DeLano WL. 2002.http://pymol.sourceforge.net.
29. Johnson ECB, Malito E, Shen Y, Pentelute B, Rich D, FlorianJ, Tang W, Kent SBH. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. J Mol Biol 2007; 373:573-586.
30. Piana S, Carloni P. Conformational flexibility of the catalytic asp dyad in HIV-1 protease: an ab initio study on the free enzyme. Proteins: Struct Funct Genet 2000; 39:26-36.